BPC-157 + TB-500 10MG

Product Overview

BPC-157 + TB-500 10MG is a two-component lyophilised blend containing BPC-157 and TB-500, supplied as white to off-white lyophilised powder in a 10mg catalogue presentation (SKU BB10). This page describes the stated research identity and batch-oriented catalogue specification; it does not provide an administration protocol.

The components have separate preclinical literatures involving cell migration, extracellular-matrix responses, actin-associated pathways and tissue models. Those studies do not establish the behaviour of the combined formulation.

Identity and Specifications

• Product: BPC-157 + TB-500 10MG
• SKU: BB10
• Format: White to off-white lyophilised powder
• Synonyms: BPC-157 + TB-500, Body Protection Compound-157 + Thymosin Beta-4 Fragment
• Composition: BPC-157 5mg + TB-500 5mg
• Component verification: See linked Janoshik COA
• Total amount: 10mg

Catalogue Distinction

This is the 10mg listing for this identity. The related BPC-157 + TB-500 20mg listing has a different labelled amount or volume and a separate SKU. The amount difference is not a dose recommendation. Unless a batch certificate states otherwise, the scientific identity and research limitations are shared while the quantity supplied differs.

Research Context

The following themes summarise published research on the named molecule or components. They are research contexts, not claims about the supplied ExtolX batch.

Areas of Research

• component identity and ratio verification
• fibroblast, migration and matrix models
• actin-associated and angiogenic signalling
• combined-formulation compatibility and stability

Evidence Quality and Limitations

BPC-157 and TB-500 evidence is predominantly cell and animal based. The blend has a more limited direct evidence base, so combined or synergistic effects must not be assumed.

Storage and Handling

Before reconstitution: Keep the sealed lyophilised blend dry and protected from light at −20°C or below, subject to the batch-specific supplier documentation. Storage data for BPC-157 and TB-500 do not establish the stability of the combined formulation.

After reconstitution: No reliable blend-specific stability period has been verified. Do not combine the component shelf lives or infer a hold time from either component. Validate the solvent, concentration, pH, container, temperature and hold time for the complete blend. Where the validated method supports frozen storage, use single-use aliquots and avoid vigorous agitation and repeated freeze–thaw cycles. Record the preparation and storage history.

Compatibility Limitations

Do not infer solubility or stability from another peptide, blend, amount or pharmaceutical formulation. Use small-scale method development and appropriate analytical controls before committing valuable material.

Laboratory Safety

Handle only in an appropriately equipped laboratory by trained personnel. Use a task-specific risk assessment, suitable personal protective equipment and applicable safety documentation. Avoid ingestion, inhalation, skin contact and environmental release, and dispose of waste in accordance with local requirements.

Sources

• Technical storage references for the components: BPC-157 and TB-500
• PubMed: BPC-157 and tendon-fibroblast migration
• PubMed: TB-500 fragment characterisation
• PubMed: BPC-157 preclinical review
• PubMed: Biological activities of thymosin beta-4

Scientific sources last reviewed: 23 August 2026.

Research Use Agreement & Disclaimer

For laboratory research use only. Not for human or veterinary use. Purchasers are responsible for lawful handling, storage and disposal in accordance with applicable regulations and good laboratory practice. Product information is educational and is not medical advice or evidence of efficacy.